Get the Stockscreener App
45.46
2.57%
-1.20
After Hours:
45.46
Supernus Pharmaceuticals Inc stock is traded at $45.46, with a volume of 415.08K.
It is down -2.57% in the last 24 hours and up +10.23% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$46.66
Open:
$46.47
24h Volume:
415.08K
Relative Volume:
0.51
Market Cap:
$2.55B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
42.50
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
-1.17%
1M Performance:
+10.23%
6M Performance:
+44.87%
1Y Performance:
+47.12%
1-Day Range:
$45.39
$46.67
1-Week Range:
$45.26
$46.78
52-Week Range:
$29.16
$46.78
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
45.46 | 2.59B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio - MSN
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum? - Yahoo Finance
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceut - PharmiWeb.com
Published on: 2025-09-08 10:08:24 - beatles.ru
Will Supernus Pharmaceuticals Inc. benefit from rising consumer demandPortfolio Return Summary & High Conviction Buy Zone Picks - خودرو بانک
Stock Analysis: Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesJuly 2025 Outlook & Daily Chart Pattern Signal Reports - خودرو بانک
How to use a screener to detect Supernus Pharmaceuticals Inc. breakouts2025 Sector Review & AI Based Buy/Sell Signal Reports - Newser
Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesEarnings Recap Summary & Precise Buy Zone Tips - خودرو بانک
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Can Supernus Pharmaceuticals Inc. expand into new markets2025 Price Targets & Free Community Supported Trade Ideas - خودرو بانک
Analyzing recovery setups for Supernus Pharmaceuticals Inc. investorsMarket Trend Review & Daily Stock Momentum Reports - Newser
Will Supernus Pharmaceuticals Inc. benefit from sector rotationJuly 2025 Gainers & AI Driven Stock Movement Reports - خودرو بانک
Analyzing net buyer seller activity in Supernus Pharmaceuticals Inc.July 2025 Sentiment & Weekly Breakout Stock Alerts - Newser
What’s the beta of Supernus Pharmaceuticals Inc. stockMarket Trend Report & Weekly Return Optimization Alerts - خودرو بانک
Has Supernus Pharmaceuticals Inc. found a price floorWeekly Profit Summary & Daily Chart Pattern Signals - Newser
How high can Supernus Pharmaceuticals Inc. stock goJuly 2025 PreEarnings & Real-Time Price Movement Reports - Newser
Supernus at Wells Fargo Conference: Strategic Growth in CNS By Investing.com - Investing.com Canada
Will Supernus Pharmaceuticals Inc. benefit from geopolitical trends2025 Investor Takeaways & Low Risk Growth Stock Ideas - خودرو بانک
Published on: 2025-09-04 06:09:28 - Newser
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Predicting Supernus Pharmaceuticals Inc. trend using moving averagesMarket Risk Analysis & Long-Term Safe Investment Ideas - Newser
How sentiment analysis helps forecast Supernus Pharmaceuticals Inc.July 2025 Setups & High Yield Equity Trading Tips - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
Will earnings trigger a reversal in Supernus Pharmaceuticals Inc.July 2025 Summary & Safe Capital Preservation Plans - Newser
Will Supernus Pharmaceuticals Inc. benefit from seasonalityMarket Sentiment Review & Reliable Entry Point Alerts - خودرو بانک
Real time breakdown of Supernus Pharmaceuticals Inc. stock performanceNew Guidance & Intraday High Probability Alerts - Newser
Supernus Pharmaceuticals stock hits 52-week high at $45.85 By Investing.com - Investing.com Canada
Risk vs reward if holding onto Supernus Pharmaceuticals Inc.July 2025 Pullbacks & High Conviction Buy Zone Alerts - Newser
Custom strategy builders for tracking Supernus Pharmaceuticals Inc.July 2025 Final Week & Technical Pattern Recognition Alerts - Newser
How to build a custom watchlist for Supernus Pharmaceuticals Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Sector ETF performance correlation with Supernus Pharmaceuticals Inc.2025 Price Action Summary & AI Driven Price Predictions - Newser
Candlestick signals on Supernus Pharmaceuticals Inc. stock today2025 Technical Patterns & Real-Time Buy Signal Notifications - Newser
Will Supernus Pharmaceuticals Inc. stock recover after earnings2025 Market Overview & Low Risk Profit Maximizing Plans - خودرو بانک
Supernus Pharmaceuticals stock hits 52-week high at $45.85 - Investing.com
EV Market: What are Supernus Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Return Report & Detailed Earnings Play Strategies - خودرو بانک
Using data filters to optimize entry into Supernus Pharmaceuticals Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
What hedge funds are buying Supernus Pharmaceuticals Inc.July 2025 Decliners & AI Driven Price Forecasts - خودرو بانک
Is Supernus Pharmaceuticals Inc. stock showing strong momentum2025 Biggest Moves & Daily Profit Maximizing Tips - خودرو بانک
What technical models suggest about Supernus Pharmaceuticals Inc.’s comebackPrice Action & Reliable Entry Point Trade Alerts - Newser
Market Outlook: What is the long term forecast for Supernus Pharmaceuticals Inc. stockBear Alert & Safe Entry Momentum Stock Tips - خودرو بانک
What are Supernus Pharmaceuticals Inc.’s earnings expectationsWeekly Risk Report & Stepwise Trade Execution Plans - خودرو بانک
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):